Recently, another study demonstrated that galectin-3 knockdown potentiates the response to gefitinib (EGFR-tyrosine kinase inhibitor) treatment in esophageal squamous cancer cells, a type of cancer that overexpresses EGFR. This evidence concerns the gene EGFR and cancer.